HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Raises Price Target to $16
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and raises the price target from $11 to $16.
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and raises the price target from $11 to $16.